OIG Issues Semiannual Report to Congress

Conclusion As written in a January 2017 article in Life Science Compliance Update, it is too soon to tell the effect the Trump Administration will have on the pharmaceutical industry. This report and the recommendations contained therein highlight some of the focuses of OIG, but those have the propensity to change, depending on the incoming Administration.        Related Stories21st Century Bill Headed to President Obama’s DeskLeahy, Wyden Send Letter to DOJ Regarding DEA Enforcement ActionsAHR Holds Congressional Briefing Focused on Cost Growth 
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs